Vanda Pharmaceuticals Inc (VM4.SG)
| Previous close | 4.3800 |
| Open | 4.3400 |
| Bid | 4.2800 x 250000 |
| Ask | 4.4000 x 250000 |
| Day's range | 4.2600 - 4.3400 |
| 52-week range | 3.0400 - 6.2500 |
| Volume | |
| Avg. volume | 154 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.
- Reuters
UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer. Last week, Vanda rejected contract manufacturer Future Pak's offer of $7.25 to $7.75 per share in cash, which represents a 59%-70% premium to Wednesday's closing price, and adopted a shareholder rights plan to avert a hostile takeover attempt. Shareholder Capital, which owns 200,000 outstanding shares of Vanda, asked in its letter, "on what basis did the Board reject Future Pak's offer, which values Vanda shares at nearly 2x their unaffected price."
- GlobeNewswire
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Reminds Vanda’s Board of Their Fiduciary Duties Given the Mishandling of Future Pak’s Offer to Acquire Vanda’s Underperforming and Undervalued Shares at an ~80-90% Premium Expresses Serious Concerns Over Entrenchment, Misaligned Incentives, and Cronyism at Vanda, Including the CEO’s and His Family’s $46M+ in Disclosed Compensation Amidst $1B+ in Shareholder Value Destruction Believes Vanda’s Board Must Explore Strategic Alternatives MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Shareholder Capital L
